Important: VAERS reports alone cannot determine if a vaccine caused an adverse event. Reports may contain incomplete, inaccurate, or unverified information. Correlation does not equal causation.
#2287 most reported symptom for this vaccine
Increased viscosity of upper respiratory secretion has been reported 80 times in association with COVID-19 Vaccine vaccination in VAERS. This represents 0.0% of all 1,121,388 reports for this vaccine.
Among these reports, 3 mentioned death (3.75%) and 12 involved hospitalization (15.0%).
Increased viscosity of upper respiratory secretion is the #2287 most frequently reported symptom for COVID-19 Vaccine out of 9223 total symptoms.
Disclaimer: VAERS reports describe events that occurred after vaccination but do not establish that the vaccine caused the event. Many reported symptoms may be coincidental or related to underlying conditions.
Seeing 80 reports of Increased viscosity of upper respiratory secretion after COVID-19 Vaccine vaccination may seem alarming, but context is critical. With 1,121,388 total reports for this vaccine (representing many millions of doses), Increased viscosity of upper respiratory secretion appears in only 0.0% of reports.
The mortality rate of 3.75% warrants monitoring, though VAERS deaths represent temporal associations, not confirmed causal links.
This data comes from the Vaccine Adverse Event Reporting System (VAERS), jointly managed by CDC and FDA.